Efficacy of Twice Weekly Hemodialysis in Patients With Residual Kidney Function
2 other identifiers
interventional
58
1 country
3
Brief Summary
The study will determine the efficacy of twice weekly hemodialysis in patients with residual kidney function.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jul 2018
Longer than P75 for not_applicable
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2018
CompletedFirst Submitted
Initial submission to the registry
March 10, 2019
CompletedFirst Posted
Study publicly available on registry
March 14, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
May 31, 2025
CompletedResults Posted
Study results publicly available
September 3, 2025
CompletedSeptember 3, 2025
August 1, 2025
6.2 years
March 10, 2019
July 7, 2025
August 13, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
QOL: Kidney Disease Quality of Life (KDQOL36)
Kidney Disease Quality of Life: Health-related quality of life, with higher scores being better. Minimum is 0, maximum is 100.
4 weeks
Secondary Outcomes (4)
Solute Concentration
4 weeks
Symptom
4 weeks
Trail B Making Test
4 weeks
Digit Symbol Substitution Test
4 weeks
Study Arms (2)
Twice Weekly Hemodialysis then Thrice Weekly Hemodialysis
OTHERTwice weekly hemodialysis for 4 weeks, then thrice weekly hemodialysis for 4 weeks.
Thrice Weekly Hemodialysis then Twice Weekly Hemodialysis
OTHERThrice weekly hemodialysis for 4 weeks, then twice weekly hemodialysis for 4 weeks.
Interventions
Twice weekly hemodialysis for 4 weeks, then thrice weekly hemodialysis for 4 weeks.
Thrice weekly hemodialysis for 4 weeks, then twice weekly hemodialysis for 4 weeks.
Eligibility Criteria
You may qualify if:
- patients on hemodialysis who have residual kidney function with residual urea clearance (Kru) \>2.5 mL/min.
- been on hemodialysis for at least 3 months.
- adherence to regular dialysis treatments.
You may not qualify if:
- inability to achieve adequate hemodialysis.
- planned revision of hemodialysis vascular access.
- hospitalized within the past 2 months.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (3)
VA Palo Alto Health Care System
Palo Alto, California, 94304, United States
Santa Clara Valley Medical Center
San Jose, California, 95128, United States
Satellite HealthCare
San Jose, California, 95128, United States
Related Publications (1)
Lee S, Pham NM, Montez-Rath ME, Bolanos CG, Bonde SS, Meyer TW, Sirich TL. Twice Weekly versus Thrice Weekly Hemodialysis-A Pilot Cross-Over Equivalence Trial. Clin J Am Soc Nephrol. 2024 Sep 1;19(9):1159-1168. doi: 10.2215/CJN.0000000000000507. Epub 2024 Jun 26.
PMID: 38922689DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Tammy Sirich
- Organization
- VA Palo Alto
Study Officials
- PRINCIPAL INVESTIGATOR
Tammy Sirich, MD
Stanford/VA Palo Alto Health Care System
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
March 10, 2019
First Posted
March 14, 2019
Study Start
July 1, 2018
Primary Completion
September 1, 2024
Study Completion
May 31, 2025
Last Updated
September 3, 2025
Results First Posted
September 3, 2025
Record last verified: 2025-08